RxDoctor Payments Data

Diana Sun, MD

Dermatology · Flushing, NYNPI 1952485526

Payments from drug & device makers

$2,055in general payments, 2019–2025

Across 80 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$535
  • Galderma Laboratories, L.p.$235
  • Incyte Corporation$182
  • Dermavant Sciences, Inc.$174
  • Pfizer$170
  • Arcutis Biotherapeutics, Inc.$145
  • plus $614 from 11 others

What the payments were for

  • Food & beverage$1,92794%
  • Education$1286%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,055 in reported general payments places this provider in the 45th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$45,477
Medicare patients
120
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$62,093
Dupixent SyringeDupilumab12$44,313
Tacrolimus66$12,247
Pimecrolimus25$6,225
Ciclopirox96$4,210
Clobetasol Propionate61$2,838
Calcipotriene14$2,089
Halobetasol Propionate40$2,053
Fluocinonide45$1,801
Ketoconazole123$1,356
Azelaic Acid11$1,343
CiclopiroxCiclopirox Olamine38$1,293
Triamcinolone Acetonide89$1,059
Metronidazole19$1,042
Ammonium Lactate32$1,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$117$62,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,151 dermatology providers in New York.

Other dermatology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →